2024-06-10 | SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD | 13,05 | +3,07 |
2024-06-10 | SPH Notification from Ognian Donev in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD | 13,05 | +3,07 |
2024-06-06 | SPH Notification from Ognian Donev in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD | 13,30 | -1,88 |
2024-06-06 | SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD | 13,30 | -1,88 |
2024-06-06 | SPH Notification from Donev Investments Holding AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD | 13,30 | -1,88 |
2024-06-06 | SPH Notification from Telso AD in accordance with Regulation 596/2014 for transactions with shares of Sopharma AD | 13,30 | -1,88 |
2024-06-05 | SPH Notification from Ognian Donev in accordance with Regulation 596/2014 | 13,50 | -3,33 |
2024-05-30 | SPH Consolidated financial report according to IFRS as at 31 March 2024 | 13,30 | 0,00 |
2024-05-27 | SPH Invitation and Materials for Annual General Meeting of Shareholders of Sopharma AD | 13,05 | +1,15 |
2024-05-21 | SPH Sales revenues for April 2024 | 13,05 | 0,00 |
2024-04-30 | SPH Individual financial report according to IFRS as at 31 March 2024 | 13,05 | 0,00 |
2024-04-25 | SPH Publication of Annual consolidated audited financial report of "Sopharma" AD for 2023 in ESF format | 13,05 | 0,00 |
2024-04-22 | SPH Sales revenues of Sopharma AD for March 2024 | 13,70 | 0,00 |
2024-04-01 | SPH Presentation of the Annual Audited Individual Financial Statements of “Sopharma” AD as at 31 December 2022 | 13,40 | 0,00 |
2024-03-20 | SPH Sales revenues for February 2024 | 14,40 | -3,13 |
2024-03-12 | SPH Incoming transfer from capital increase subject to exercise of warrants from issue BG9200001212 | 14,00 | -1,43 |
2024-03-11 | SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 08 March 2024 on the acquisition of shares from a capital increase | 13,80 | +1,45 |
2024-02-29 | SPH Consolidated financial report as of 31 December 2023 | 13,70 | -2,19 |
2024-02-27 | SPH Results of conditional capital increase of Sopharma AD by exercising warrants from an issue with ISIN BG9200001212 | 13,40 | +2,99 |
2024-02-22 | SPH Notification from "Donev Investments Holding" AD under Art. 19 of Regulation (EU) No. 596/2014 of 19 February 2024 on the acquisition of shares from a temporary issue/exercise of warrants | 13,75 | -0,73 |
